C
Caribou Biosciences
Biotechnology company focused on genome engineering and developing technology-based solutions for cells
At a glance
- Status
- Listed
- Listing
- IPO 2021
Open roles
Caribou Biosciences in the Berkeley ecosystem
The Caribou Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- GVGenoa Ventures
David Beyer
Maverick Ventures- E-E-Merge
- NONovartis
Marc Bell Capital
Series B and later23 investors entered at this stage
F-PrimeJanus Henderson Investors
- TMTekla Capital Management
- FMFarallon Capital Management
- ACAvego Bioscience Capital
- LPLifeSci Venture Partners
- APAvidity Partners
- MMMonashee Investment Management
- PAPontifax AgTech
- RCRidgeback Capital
- ABAbbVie
- MCMission Bay Capital
- ACAdage Capital
- HSHeritage Medical Systems
- TSThe Leukemia & Lymphoma Society
- PVPoint72 Ventures
- MCMaverick Capital
- ACAnterra Capital
- UCUniversity of California
- BEBerkeley
- PSPFM Health Sciences
- INInvus
- HGHeritage Group
Source: Dealroom Talent Intelligence.
Alumni founders
Former Caribou Biosciences employees who went on to found companies, sorted by Dealroom signal score.
ITIntellia TherapeuticsEst. 2014
LBLaguna BioEst. 2022
Jonathan KotulaUnited States
LBLocus BiosciencesEst. 2015
Rodolphe Barrangou.United States
Richard ChinUnited States
EMEditas MedicineEst. 2013
Jennifer A. DoudnaUnited StatesPatents
33 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Caribou Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
MaxCyte secures $75M credit facility to fund Akron Bio acquisition
